Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Targeted Therapy | Research article

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China

Authors: Ruofei Du, Xin Wang, Lixia Ma, Leon M. Larcher, Han Tang, Huiyue Zhou, Changying Chen, Tao Wang

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data.

Methods

A retrospective secondary data analysis was conducted within an ADR data set including 2703 patients with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate logistic regression with backward stepwise method were applied to assess the difference of pathological characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of overall survival was performed to compare the clinical outcomes between these two groups.

Results

A total of 485 patients were enrolled in this study. Of all patients, 61.0% (n = 296) occurred ADRs including skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within one month, 68.6% ADRs lasted more than one month. Older patients (P = 0.022) and patients with lower education level (P = 0.036), more than 2 comorbidities (P = 0.021), longer medication time (P = 0.022), drug combination (P = 0.033) and intravenous administration (P = 0.019) were more likely to have ADRs. Those with ADRs were more likely to stop taking (P = 0.000), change (P = 0.000), adjust (P = 0.000), or not take the medicine on time (P = 0.000). The number of patients with recurrence (P = 0.000) and metastasis (P = 0.006) were statistically significant difference between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared with non-ADRs group.

Conclusion

The high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We should pay more attention to these ADRs and develop effective management strategies.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Lindsey S. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Lindsey S. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Yang D, Yang L, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 2020;468(5):82–7.CrossRef Yang D, Yang L, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 2020;468(5):82–7.CrossRef
3.
go back to reference Estève J, Kricker F, Jacques MD. Facts and figures of Cancer in the European Community. Can J Neurol Sci. 2015;42(5):338–40.CrossRef Estève J, Kricker F, Jacques MD. Facts and figures of Cancer in the European Community. Can J Neurol Sci. 2015;42(5):338–40.CrossRef
4.
go back to reference Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56(5):1–7.CrossRef Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56(5):1–7.CrossRef
5.
go back to reference Wilkes GM. Targeted therapy attacking Cancer with molecular and immunological targeted agents. Asia Pac J Oncol Nurs. 2018;5(2):137–55.CrossRef Wilkes GM. Targeted therapy attacking Cancer with molecular and immunological targeted agents. Asia Pac J Oncol Nurs. 2018;5(2):137–55.CrossRef
6.
go back to reference Bhullar KS, Lagarón NO, Mcgowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48–57.CrossRef Bhullar KS, Lagarón NO, Mcgowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48–57.CrossRef
7.
go back to reference Kris MG, Johnson BE, Berry LD, Kaldal A. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:2998–3006.CrossRef Kris MG, Johnson BE, Berry LD, Kaldal A. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:2998–3006.CrossRef
8.
go back to reference Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung Cancer using a Clinicogenomic database. JAMA. 2019;321(14):1391–402.CrossRef Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung Cancer using a Clinicogenomic database. JAMA. 2019;321(14):1391–402.CrossRef
9.
go back to reference Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–25.CrossRef Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–25.CrossRef
10.
go back to reference Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651–60.CrossRef Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651–60.CrossRef
11.
go back to reference Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med-Us. 2014;3(6):1517–26.CrossRef Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med-Us. 2014;3(6):1517–26.CrossRef
12.
go back to reference CLELL, HASENBANK. Supportive care and Management of Treatment-Emergent Adverse Events with Targeted Therapy in non-small cell lung Cancer. J Adv Pract Oncol. 2017;8(1):43–50. CLELL, HASENBANK. Supportive care and Management of Treatment-Emergent Adverse Events with Targeted Therapy in non-small cell lung Cancer. J Adv Pract Oncol. 2017;8(1):43–50.
13.
go back to reference Bo Z, Fang C, Deng D, Liang X. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett. 2018;16(1):27–33. Bo Z, Fang C, Deng D, Liang X. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett. 2018;16(1):27–33.
14.
go back to reference Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Tr. 2019;483–494:176. Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Tr. 2019;483–494:176.
15.
go back to reference Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729–40.CrossRef Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729–40.CrossRef
16.
go back to reference Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin N Am. 2017;1(52):83–113.CrossRef Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin N Am. 2017;1(52):83–113.CrossRef
17.
go back to reference Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(S1):31–9.CrossRef Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(S1):31–9.CrossRef
18.
go back to reference Armstrong, Terri S. Symptoms Experience: A concept analysis. Oncol Nurs Forum. 2003;30(4):601–6.CrossRef Armstrong, Terri S. Symptoms Experience: A concept analysis. Oncol Nurs Forum. 2003;30(4):601–6.CrossRef
19.
go back to reference Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas. 2020;112(1):12–22. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas. 2020;112(1):12–22.
20.
go back to reference Brown DEG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.CrossRef Brown DEG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.CrossRef
21.
go back to reference Muro YNK. Challenges in molecular targeted therapy for gastric cancer considerations for efficacy and safety. Expert Opin Drug Saf. 2016;16(3):319–27.PubMed Muro YNK. Challenges in molecular targeted therapy for gastric cancer considerations for efficacy and safety. Expert Opin Drug Saf. 2016;16(3):319–27.PubMed
22.
go back to reference Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020 2020-05-01; 40:485–500. Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020 2020-05-01; 40:485–500.
23.
go back to reference Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10(52):1259–73.CrossRef Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10(52):1259–73.CrossRef
24.
go back to reference Anna J. Lomax, Theresa Nielsen, MCaHaem N, Lydia Visintin. Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy. Clin J Oncol Nurs. 2017 2017-08-01; 21(4):E93–E98. Anna J. Lomax, Theresa Nielsen, MCaHaem N, Lydia Visintin. Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy. Clin J Oncol Nurs. 2017 2017-08-01; 21(4):E93–E98.
25.
go back to reference Daud A, Tsai K. Management of Treatment-Related Adverse Events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017;22(19):1–11. Daud A, Tsai K. Management of Treatment-Related Adverse Events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017;22(19):1–11.
26.
go back to reference Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol. 2018;35(2):16–25.CrossRef Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol. 2018;35(2):16–25.CrossRef
27.
go back to reference Damiani G, Manganoni A, Cazzaniga S, Naldi L. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. G Ital Dermatol Venereol. 2018;11(5):357–65. Damiani G, Manganoni A, Cazzaniga S, Naldi L. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. G Ital Dermatol Venereol. 2018;11(5):357–65.
28.
go back to reference Brunot AL, Le Roy F, Le Sourd S, Amel M Sadek, Marielle Duval, Laurence Crouzet, et al. Implementation of a nurse-driven educational program improves management. Cancer Nurs. 2018;41(5):418–23.CrossRef Brunot AL, Le Roy F, Le Sourd S, Amel M Sadek, Marielle Duval, Laurence Crouzet, et al. Implementation of a nurse-driven educational program improves management. Cancer Nurs. 2018;41(5):418–23.CrossRef
29.
go back to reference Staats H, Cassidy C, Kelso J, Mack S. Targeted molecular therapy in palliative Cancer management. Biomedicine. 2020;5(13):27–49. Staats H, Cassidy C, Kelso J, Mack S. Targeted molecular therapy in palliative Cancer management. Biomedicine. 2020;5(13):27–49.
30.
go back to reference Chan J, Lee Y, Liu C, Shih H. A correlational study of skin toxicity and quality of life in patients with advanced lung Cancer receiving targeted therapy. J Nurs Res. 2019;27(6):e51–9.CrossRef Chan J, Lee Y, Liu C, Shih H. A correlational study of skin toxicity and quality of life in patients with advanced lung Cancer receiving targeted therapy. J Nurs Res. 2019;27(6):e51–9.CrossRef
31.
go back to reference Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P, Brandi G. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. J Toxicol Cutaneous Ocular Toxicol. 2014;33(1):1–6.CrossRef Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P, Brandi G. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. J Toxicol Cutaneous Ocular Toxicol. 2014;33(1):1–6.CrossRef
32.
go back to reference Chan SL, Ang X, Sani LL, Hong YN, Chan A. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharm. 2016;82(6):1636–46.CrossRef Chan SL, Ang X, Sani LL, Hong YN, Chan A. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharm. 2016;82(6):1636–46.CrossRef
33.
go back to reference Gervès-Pinquié C, Daumas-Yatim F, Lalloué B, Girault A, Ferrua M, Fourcade A, et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy the CAPRI randomized controlled trial. BMC Health Serv Res. 2017;133(17):286–93. Gervès-Pinquié C, Daumas-Yatim F, Lalloué B, Girault A, Ferrua M, Fourcade A, et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy the CAPRI randomized controlled trial. BMC Health Serv Res. 2017;133(17):286–93.
34.
go back to reference Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.CrossRef Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.CrossRef
35.
go back to reference Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–7.CrossRef Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–7.CrossRef
36.
go back to reference Fornasier G, Taborelli M, Francescon S, Polesel J, Aliberti M, De Paoli P, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm-Net. 2018;40(5):795–802.CrossRef Fornasier G, Taborelli M, Francescon S, Polesel J, Aliberti M, De Paoli P, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm-Net. 2018;40(5):795–802.CrossRef
Metadata
Title
Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China
Authors
Ruofei Du
Xin Wang
Lixia Ma
Leon M. Larcher
Han Tang
Huiyue Zhou
Changying Chen
Tao Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07946-x

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine